Global Head and Neck Squamous Cell Carcinoma Drugs Market US$ 1.

5 Billion 2021

The global head and neck squamous cell carcinoma drugs market expected to reach US$ 1.5 billion by 2021, growing
at CAGR 23.5% over the forecast period 2017-2021, mainly due to rising epidemic of oropharynx cancer associated
with the human papillomavirus.

Head and neck cancer is common in several regions of the world. The annual incidence of head and neck cancers
worldwide is more than 550,000 cases each year. About 90% of all head and neck cancers are squamous cell
carcinomas. HNSCC is the sixth leading cancer by incidence worldwide. The primary risk factors associated with head
and neck cancer include tobacco use, alcohol consumption, human papillomavirus (HPV) infection (for
oropharyngeal cancer), and Epstein-Barr virus (EBV) infection (for nasopharyngeal cancer). Head and neck cancer
accounts for about 3% of all cancers in the United States. In 2016, an estimated 63,030 people (46,290 men and
16,740 women) have developed head and neck cancer, whereas in 2017, an estimated 129,800 patients will be
diagnosed with SCCHN in the United States, five major European markets and Japan.

Treatment options include single-agent therapy and combination regimens using either conventional cytotoxic
chemotherapy and/or molecularly targeted agents combined with best supportive care. Checkpoint inhibitor
immunotherapy is an option for patients with progressive disease after their initial chemotherapy regimen.
Historically, the most widely used agents include platinum compounds (cisplatin, carboplatin), taxanes (docetaxel,
paclitaxel, abraxane), methotrexate, fluorouracil, and cetuximab. Pembrolizumab and nivolumab, checkpoint
inhibitors of programmed cell death protein 1 (PD-1) have also been approved. Keytruda (pembrolizumab); Merck;
For the treatment of head and neck squamous cell cancer, Approved August 2016. On November 10, 2016, the U. S.
Food and Drug Administration approved nivolumab (OPDIVO Injection, Bristol-Myers Squibb Company), for the
treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with
disease progression on or after a platinum-based therapy.

The management of advanced head and neck squamous cell carcinoma (HNSCC) consists of multiple-modality
therapy with surgery, radiation, and chemotherapy. Palliative radiation therapy is beneficial for treating
symptomatic metastatic sites. Selective drugs have been developed that target either the extracellular ligand-
binding region of the EGFR (including a number of monoclonal antibodies, immunotoxins, and ligand-binding
cytotoxic agents) or the intracellular tyrosine kinase region (including various small-molecule inhibitors). Targeted
therapies such as cetuximab, panitumumab, zalutumumab, nimotuzumab, erlotinib, gefitinib and lapatinib against
the epidermal growth factor receptor (EGFR) are the most promising molecular therapeutics for head and neck
squamous cell carcinoma. Drugs commonly used as single agents in the treatment include docetaxel, paclitaxel,
cetuximab, capecitabine, pemetrexed, and methotrexate. Two checkpoint inhibitors or programmed cell death
protein 1 (PD1) inhibitors, Pembrolizumab (Keytruda), manufactured by Merck & Co. and Nivolumab (Opdivo),
manufactured by Bristol-Myers Squibb received FDA accelerated approval in 2016. New therapies include mTOR
inhibitors, anti-angiogenic agents, and IGF1R inhibitors.

Drugs approved for head and neck cancer include Abitrexate (Methotrexate), Blenoxane (Bleomycin), Bleomycin,
Cetuximab, Docetaxel, Erbitux (Cetuximab), Folex (Methotrexate), Folex PFS (Methotrexate), Hydrea (Hydroxyurea),
Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Methotrexate LPF (Methotrexate), Mexate
(Methotrexate), Mexate-AQ (Methotrexate), Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere
(Docetaxel). Drug combinations used in head and neck cancer include TPF - Docetaxel (Taxotere), Cisplatin (Platinol),
and Fluorouracil. Drugs in the phase III clinical pipeline for SCCHN include Avelumab, Durvalumab, Gilotrif/Giotrif
(afatinib), Multikine (leukocyte interleukin), Tremelimumab, and Yervoy (ipilimumab). The immune checkpoint
inhibitors (durvalumab, tremelimumab, ipilimumab and avelumab) are expected to obtain approval by 2021.

Browse Head and Neck Squamous Cell Carcinoma Drugs Market by Drug Class - Cytotoxic Agents, Epidermal
Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 (PD1) Inhibitors, PD1 Ligand 1 (PDL1)
Inhibitors, Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Inhibitors and Forecast 2017-2021 at
https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/
The global head and neck squamous cell carcinoma drugs market research report provides market size (Revenue
USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global
head and neck squamous cell carcinoma drugs market research report is further segmented by geography into North
America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain), Latin America (Brazil, Mexico, Rest of LA), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global head and neck squamous
cell carcinoma drugs market report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or
countries. The report also tracks the major competitors operating in the global market by company overview,
financial snapshot, major products, technologies, services offered and recent developments. Major players
operating in the global head and neck squamous cell carcinoma drugs market and profiled in this report include
Advaxis, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CEL-SCI, Five Prime Therapeutics, Incyte, IRX
Therapeutics, MacroGenics, Merck KGaA, Novartis, Ono Pharmaceuticals (BMS), and Pfizer.

1. Drug Class
1.1. Cytotoxic Agents
1.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
1.3. Programmed Cell Death Protein 1 (PD1) Inhibitors
1.4. PD1 Ligand 1 (PDL1) Inhibitors
1.5. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Inhibitors

2. Geography
2.1. North America (U.S., Canada)
2.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.3. Latin America (Brazil, Mexico, Rest of LA)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Advaxis
3.2. AstraZeneca
3.3. Boehringer Ingelheim
3.4. Bristol-Myers Squibb
3.5. CEL-SCI
3.6. Five Prime Therapeutics
3.7. Incyte
3.8. IRX Therapeutics
3.9. MacroGenics
3.10. Merck KGaA
3.11. Novartis
3.12. Ono Pharmaceuticals (BMS)
3.13. Pfizer

To request Table of Contents and Sample Pages of this report visit:

https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/